{"pmid":32504747,"title":"Cardiovascular complications in COVID-19: A systematic review and meta-analysis.","text":["Cardiovascular complications in COVID-19: A systematic review and meta-analysis.","J Infect","Kunutsor, Setor K","Laukkanen, Jari A","32504747"],"journal":"J Infect","authors":["Kunutsor, Setor K","Laukkanen, Jari A"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504747","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.068","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668892488275853312,"score":9.490897,"similar":[{"pmid":32410807,"pmcid":"PMC7221373","title":"Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 - Systematic Review, Meta-analysis, and Meta-regression.","text":["Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 - Systematic Review, Meta-analysis, and Meta-regression.","Background We conducted this systematic review and meta-analysis to evaluate the latest evidence on the association between cerebrovascular, cardiovascular disease, and poor outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Methods A comprehensive systematic literature search was performed using PubMed, SCOPUS, EuropePMC, and Cochrane Central Database. The outcome of interest was composite poor outcome that comprised of mortality and severe COVID-19. Results A total of 4448 patients were obtained from 16 studies. Cerebrovascular disease was associated with increased poor composite outcome (RR 2.04 [1.43, 2.91], p<0.001; I(2): 77%). Subgroup analysis revealed that cerebrovascular disease was associated with mortality (RR 2.38 [1.92, 2.96], p<0.001; I(2): 0%) and was borderline significant for severe COVID-19 (RR 1.88 [1.00, 3.51], p=0.05; I(2): 87%). Cardiovascular disease was associated with increased composite poor outcome (RR 2.23 [1.71, 2.91], p<0.001; I(2): 60%), and its mortality (RR 2.25 [1.53, 3.29], p<0.001; I(2): 33%) and severe COVID-19 (RR 2.25 [1.51, 3.36], p<0.001; I(2): 76%) subgroup. Meta-regression demonstrate that the association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. The association between cerebrovascular disease and poor outcome was not affected by cardiovascular diseases and vice versa. Conclusion Cerebrovascular and cardiovascular diseases were associated with increased risk for poor outcome in COVID-19.","J Stroke Cerebrovasc Dis","Pranata, Raymond","Huang, Ian","Lim, Michael Anthonius","Wahjoepramono, Prof Eka Julianta","July, Julius","32410807"],"abstract":["Background We conducted this systematic review and meta-analysis to evaluate the latest evidence on the association between cerebrovascular, cardiovascular disease, and poor outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Methods A comprehensive systematic literature search was performed using PubMed, SCOPUS, EuropePMC, and Cochrane Central Database. The outcome of interest was composite poor outcome that comprised of mortality and severe COVID-19. Results A total of 4448 patients were obtained from 16 studies. Cerebrovascular disease was associated with increased poor composite outcome (RR 2.04 [1.43, 2.91], p<0.001; I(2): 77%). Subgroup analysis revealed that cerebrovascular disease was associated with mortality (RR 2.38 [1.92, 2.96], p<0.001; I(2): 0%) and was borderline significant for severe COVID-19 (RR 1.88 [1.00, 3.51], p=0.05; I(2): 87%). Cardiovascular disease was associated with increased composite poor outcome (RR 2.23 [1.71, 2.91], p<0.001; I(2): 60%), and its mortality (RR 2.25 [1.53, 3.29], p<0.001; I(2): 33%) and severe COVID-19 (RR 2.25 [1.51, 3.36], p<0.001; I(2): 76%) subgroup. Meta-regression demonstrate that the association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. The association between cerebrovascular disease and poor outcome was not affected by cardiovascular diseases and vice versa. Conclusion Cerebrovascular and cardiovascular diseases were associated with increased risk for poor outcome in COVID-19."],"journal":"J Stroke Cerebrovasc Dis","authors":["Pranata, Raymond","Huang, Ian","Lim, Michael Anthonius","Wahjoepramono, Prof Eka Julianta","July, Julius"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410807","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jstrokecerebrovasdis.2020.104949","keywords":["covid-19","cardiovascular","cerebrovascular","mortality","severity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666897319206846464,"score":54.958263},{"pmid":32417708,"title":"\"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.\"","text":["\"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.\"","BACKGROUNDS AND AIMS: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to all cause. METHODS: PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords up to April 30, 2020. Studies that met our objectives were assessed for the risk of bias applying various tools as indicated. Three studies each that reported the outcome of viral clearance by RT-PCR and death due to all cause, were meta-analyzed by applying inverse variance-weighted averages of logarithmic risk ratio (RR) using a random effects model. Heterogeneity and publication bias were assessed using the I(2) statistic and funnel plots, respectively. RESULTS: Meta-analysis of 3 studies (n = 210) on viral clearance assessed by RT-PCR showed no benefit (RR, 1.05; 95% CI, 0.79 to 1.38; p = 0.74), although with a moderate heterogeneity (I(2) = 61.7%, p = 0.07). While meta-analysis of 3 studies (n = 474) showed a significant increase in death with HCQ, compared to the control (RR, 2.17; 95% 1.32 to 3.57; p = 0.002), without any heterogeneity (I(2) = 0.0%, p = 0.43). CONCLUSIONS: No benefit on viral clearance but a significant increase in mortality was observed with HCQ compared to control in patients with COVID-19.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Singh, Akriti","Singh, Ritu","Misra, Anoop","32417708"],"abstract":["BACKGROUNDS AND AIMS: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to all cause. METHODS: PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords up to April 30, 2020. Studies that met our objectives were assessed for the risk of bias applying various tools as indicated. Three studies each that reported the outcome of viral clearance by RT-PCR and death due to all cause, were meta-analyzed by applying inverse variance-weighted averages of logarithmic risk ratio (RR) using a random effects model. Heterogeneity and publication bias were assessed using the I(2) statistic and funnel plots, respectively. RESULTS: Meta-analysis of 3 studies (n = 210) on viral clearance assessed by RT-PCR showed no benefit (RR, 1.05; 95% CI, 0.79 to 1.38; p = 0.74), although with a moderate heterogeneity (I(2) = 61.7%, p = 0.07). While meta-analysis of 3 studies (n = 474) showed a significant increase in death with HCQ, compared to the control (RR, 2.17; 95% 1.32 to 3.57; p = 0.002), without any heterogeneity (I(2) = 0.0%, p = 0.43). CONCLUSIONS: No benefit on viral clearance but a significant increase in mortality was observed with HCQ compared to control in patients with COVID-19."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Singh, Akriti","Singh, Ritu","Misra, Anoop"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417708","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.dsx.2020.05.017","keywords":["covid-19","death","hydroxychloroquine","outcomes","viral clearance"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667058206858280960,"score":51.083477},{"pmid":32449374,"title":"Laboratory findings of COVID-19: a systematic review and meta-analysis.","text":["Laboratory findings of COVID-19: a systematic review and meta-analysis.","The Coronavirus Disease (COVID-19) pandemic first broke out in December 2019 in Wuhan, China, and has now spread worldwide. Laboratory findings have been only partially described in some observational studies. To date, more comprehensive systematic reviews of laboratory findings on COVID-19 are missing. We performed a systematic review with a meta-analysis to assess laboratory findings in patients with COVID-19. Observational studies from three databases were selected. We calculated pooled proportions and 95% confidence interval (95% CI) using the random-effects model meta-analysis. A total of 1106 articles were identified from PubMed, Web of Science, CNKI (China), and other sources. After screening, 28 and 7 studies were selected for a systematic review and a meta-analysis, respectively. Of the 4,663 patients included, the most prevalent laboratory finding was increased C-reactive protein (CRP; 73.6%, 95% CI 65.0-81.3%), followed by decreased albumin (62.9%, 95% CI 28.3-91.2%), increased erythrocyte sedimentation rate (61.2%, 95% CI 41.3-81.0%), decreased eosinophils (58.4%, 95% CI 46.5-69.8%), increased interleukin-6 (53.1%, 95% CI 36.0-70.0%), lymphopenia (47.9%, 95% CI 41.6-54.9%), and increased lactate dehydrogenase (LDH; 46.2%, 95% CI 37.9-54.7%). A meta-analysis of seven studies with 1905 patients showed that increased CRP (OR 3.0, 95% CI: 2.1-4.4), lymphopenia (OR 4.5, 95% CI: 3.3-6.0), and increased LDH (OR 6.7, 95% CI: 2.4-18.9) were significantly associated with severity. These results demonstrated that more attention is warranted when interpreting laboratory findings in patients with COVID-19. Patients with elevated CRP levels, lymphopenia, or elevated LDH require proper management and, if necessary, transfer to the intensive care unit.","Scand J Clin Lab Invest","Zhang, Zu-Li","Hou, Yu-Lei","Li, De-Tao","Li, Feng-Zeng","32449374"],"abstract":["The Coronavirus Disease (COVID-19) pandemic first broke out in December 2019 in Wuhan, China, and has now spread worldwide. Laboratory findings have been only partially described in some observational studies. To date, more comprehensive systematic reviews of laboratory findings on COVID-19 are missing. We performed a systematic review with a meta-analysis to assess laboratory findings in patients with COVID-19. Observational studies from three databases were selected. We calculated pooled proportions and 95% confidence interval (95% CI) using the random-effects model meta-analysis. A total of 1106 articles were identified from PubMed, Web of Science, CNKI (China), and other sources. After screening, 28 and 7 studies were selected for a systematic review and a meta-analysis, respectively. Of the 4,663 patients included, the most prevalent laboratory finding was increased C-reactive protein (CRP; 73.6%, 95% CI 65.0-81.3%), followed by decreased albumin (62.9%, 95% CI 28.3-91.2%), increased erythrocyte sedimentation rate (61.2%, 95% CI 41.3-81.0%), decreased eosinophils (58.4%, 95% CI 46.5-69.8%), increased interleukin-6 (53.1%, 95% CI 36.0-70.0%), lymphopenia (47.9%, 95% CI 41.6-54.9%), and increased lactate dehydrogenase (LDH; 46.2%, 95% CI 37.9-54.7%). A meta-analysis of seven studies with 1905 patients showed that increased CRP (OR 3.0, 95% CI: 2.1-4.4), lymphopenia (OR 4.5, 95% CI: 3.3-6.0), and increased LDH (OR 6.7, 95% CI: 2.4-18.9) were significantly associated with severity. These results demonstrated that more attention is warranted when interpreting laboratory findings in patients with COVID-19. Patients with elevated CRP levels, lymphopenia, or elevated LDH require proper management and, if necessary, transfer to the intensive care unit."],"journal":"Scand J Clin Lab Invest","authors":["Zhang, Zu-Li","Hou, Yu-Lei","Li, De-Tao","Li, Feng-Zeng"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449374","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/00365513.2020.1768587","keywords":["c-reactive protein","covid-2019","sars-cov-2","laboratory findings","lactate dehydrogenase","lymphopenia"],"locations":["Wuhan","China","China","lymphopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667785214016880640,"score":51.083477},{"pmid":32461330,"title":"Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis.","text":["Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk. METHODS: PubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. RESULTS: A total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I(2)=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I(2)=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I(2)=71%). CONCLUSION: COVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted.","Heart","Li, Xintao","Guan, Bo","Su, Tong","Liu, Wei","Chen, Mengyao","Bin Waleed, Khalid","Guan, Xumin","Gary, Tse","Zhu, Zhenyan","32461330"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk. METHODS: PubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity. RESULTS: A total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I(2)=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I(2)=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I(2)=71%). CONCLUSION: COVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted."],"journal":"Heart","authors":["Li, Xintao","Guan, Bo","Su, Tong","Liu, Wei","Chen, Mengyao","Bin Waleed, Khalid","Guan, Xumin","Gary, Tse","Zhu, Zhenyan"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461330","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1136/heartjnl-2020-317062","keywords":["cardiac risk factors and prevention","epidemiology","global health","meta-analysis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668079521490796544,"score":50.65963},{"pmid":32441789,"title":"Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.","text":["Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.","Mortality rates of coronavirus disease 2019 (COVID-19) continue to rise across the world. Information regarding the predictors of mortality in COVID-19 patients remains scarce. Herein, we performed a systematic review of published articles, from January 1 to April 24, 2020, to evaluate the risk factors associated with mortality in COVID-19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (OR 2.5; 95% CI 2.1-3.1; P<0.00001), coronary heart disease (OR 3.8; 95% CI 2.1-6.9; P<0.00001) and diabetes (OR 2.0; 95% CI 1.7-2.3; P<0.00001) were associated with significantly higher risk of death amongst COVID-19 patients. Those who died, compared to those who survived, differed on multiple biomarker levels on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI 19.0-69.4; P=0.0006); C-reactive protein (+66.3 microg/mL, 95% CI 46.7-85.9; P<0.00001); interleukin-6 (+4.6 ng/mL, 95% CI 3.6-5.6; P<0.00001); D-dimer (+4.6 microg/mL, 95% CI 2.8-6.4; P<0.00001); creatinine (+15.3 micromol/L, 95% CI 6.2-24.3; P=0.001) and alanine transaminase (+5.7 U/L, 95% CI 2.6-8.8; P=0.0003); as well as decreased levels of albumin (-3.7 g/L, 95% CI -5.3 to -2.1; P<0.00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end-organ damage are at higher risk of mortality due to COVID-19 infection and should be managed with greater intensity. This article is protected by copyright. All rights reserved.","J Med Virol","Tian, Wenjie","Jiang, Wanlin","Yao, Jie","Nicholson, Christopher J","Li, Rebecca H","Sigurslid, Haakon H","Wooster, Luke","Rotter, Jerome I","Guo, Xiuqing","Malhotra, Rajeev","32441789"],"abstract":["Mortality rates of coronavirus disease 2019 (COVID-19) continue to rise across the world. Information regarding the predictors of mortality in COVID-19 patients remains scarce. Herein, we performed a systematic review of published articles, from January 1 to April 24, 2020, to evaluate the risk factors associated with mortality in COVID-19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (OR 2.5; 95% CI 2.1-3.1; P<0.00001), coronary heart disease (OR 3.8; 95% CI 2.1-6.9; P<0.00001) and diabetes (OR 2.0; 95% CI 1.7-2.3; P<0.00001) were associated with significantly higher risk of death amongst COVID-19 patients. Those who died, compared to those who survived, differed on multiple biomarker levels on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI 19.0-69.4; P=0.0006); C-reactive protein (+66.3 microg/mL, 95% CI 46.7-85.9; P<0.00001); interleukin-6 (+4.6 ng/mL, 95% CI 3.6-5.6; P<0.00001); D-dimer (+4.6 microg/mL, 95% CI 2.8-6.4; P<0.00001); creatinine (+15.3 micromol/L, 95% CI 6.2-24.3; P=0.001) and alanine transaminase (+5.7 U/L, 95% CI 2.6-8.8; P=0.0003); as well as decreased levels of albumin (-3.7 g/L, 95% CI -5.3 to -2.1; P<0.00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end-organ damage are at higher risk of mortality due to COVID-19 infection and should be managed with greater intensity. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Tian, Wenjie","Jiang, Wanlin","Yao, Jie","Nicholson, Christopher J","Li, Rebecca H","Sigurslid, Haakon H","Wooster, Luke","Rotter, Jerome I","Guo, Xiuqing","Malhotra, Rajeev"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441789","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26050","keywords":["covid-19","cardiovascular disease","diabetes","meta-analysis"],"e_drugs":["Creatinine"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667523504784801793,"score":47.58769}]}